What are the contraindications for the Mirena intrauterine system (IUS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mirena IUD Contraindications

Absolute Contraindications (Category 4)

The only absolute contraindication to Mirena insertion is confirmed or suspected pregnancy, due to the risk of severe pelvic infection and septic spontaneous abortion. 1, 2, 3

Additional absolute contraindications include:

  • Current breast cancer — Breast cancer is a hormonally sensitive tumor, making the levonorgestrel-releasing IUD contraindicated in women with active disease 1
  • Persistently elevated β-hCG levels or malignant gestational trophoblastic disease 1
  • Distorted uterine cavity from congenital or acquired anatomical abnormalities that would prevent proper device placement 4
  • Current cervical or endometrial cancer awaiting treatment — The device will likely need removal at time of treatment, and insertion poses increased risk of infection, perforation, and bleeding 1, 4

Relative Contraindications (Category 3)

These conditions warrant careful consideration but are not absolute contraindications:

  • Active sexually transmitted infections (chlamydia or gonorrhea) or purulent cervicitis — Category 3 due to increased risk of pelvic inflammatory disease with insertion 3, 4. However, STI screening can be performed on the day of insertion with treatment afterward without device removal if needed 3
  • Past breast cancer with no evidence of disease for 5 years — Category 3, though concerns about disease progression may be less with LNG-IUD than with combined oral contraceptives 1
  • Unexplained vaginal bleeding (suspicion for serious condition) before evaluation — Category 4 for initiation, Category 2 for continuation. The device does not need removal before evaluation, but underlying pathology must be ruled out 1, 5, 6

Important Category 2 Conditions (Advantages Generally Outweigh Risks)

  • Cervical intraepithelial neoplasia — Theoretical concern exists that LNG-IUD might enhance progression, though evidence is limited 1
  • Undiagnosed breast mass — Requires evaluation but not absolute contraindication 1
  • Heavy or prolonged bleeding — Category 2 for initiation, though the LNG-IUD is actually beneficial for treating menorrhagia 1, 4

Critical Clinical Pitfalls

Irregular bleeding is extremely common in initial Mirena users and may mask underlying cervical or endometrial pathology. 5, 6 Proper evaluation of irregular vaginal bleeding, including cervical cytology, should be performed before insertion and repeated if symptoms persist beyond the expected adjustment period of 3-6 months 5, 6

Past pelvic inflammatory disease, HIV infection, immunosuppression, and nulliparity are NOT contraindications to Mirena use. 1, 7 The risk of pelvic infection is confined to the first 20-21 days after insertion 3

Important Safety Warnings

  • The Mirena does not protect against sexually transmitted infections or HIV — Condoms should be used consistently if STI/HIV risk exists 2, 3, 4
  • Gestational trophoblastic disease with decreasing β-hCG is Category 3, not an absolute contraindication 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Intrauterine Device (IUD) Indications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Contraindications for the Use of Copper Intrauterine Devices

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Menstrual Control with Levonorgestrel IUD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Endometrial adenocarcinoma following insertion of the levonorgestrel-releasing intrauterine system (mirena) in a 36-year-old woman.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.